Indolin-2-one based scaffold for the development of multi- kinase inhibitor: Focus on sunitinib as an anticancer agent
Soudi, A., Abdelhafez, S., Aly, O., Ali, T. (2024). Indolin-2-one based scaffold for the development of multi- kinase inhibitor: Focus on sunitinib as an anticancer agent. EKB Journal Management System, 4(1), 1-10. doi: 10.21608/odr.2023.225166.1028
Aya Soudi; Shimaa M.N. Abdelhafez; Omar M. Aly; Taha F.S. Ali. "Indolin-2-one based scaffold for the development of multi- kinase inhibitor: Focus on sunitinib as an anticancer agent". EKB Journal Management System, 4, 1, 2024, 1-10. doi: 10.21608/odr.2023.225166.1028
Soudi, A., Abdelhafez, S., Aly, O., Ali, T. (2024). 'Indolin-2-one based scaffold for the development of multi- kinase inhibitor: Focus on sunitinib as an anticancer agent', EKB Journal Management System, 4(1), pp. 1-10. doi: 10.21608/odr.2023.225166.1028
Soudi, A., Abdelhafez, S., Aly, O., Ali, T. Indolin-2-one based scaffold for the development of multi- kinase inhibitor: Focus on sunitinib as an anticancer agent. EKB Journal Management System, 2024; 4(1): 1-10. doi: 10.21608/odr.2023.225166.1028

Indolin-2-one based scaffold for the development of multi- kinase inhibitor: Focus on sunitinib as an anticancer agent

Octahedron Drug Research
Volume 4, Issue 1, January 2024, Page 1-10  XML PDF (502.98 K)
Document Type: Review Articles
DOI: 10.21608/odr.2023.225166.1028
View on SCiNiTO View on SCiNiTO
Authors
Aya Soudi email 1; Shimaa M.N. Abdelhafez2; Omar M. Alyorcid 3; Taha F.S. Ali4
1medicinal chemistry department ,faculty of pharmacy ,Minia university ,Minia ,Egypt
2Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519-Minia, Egypt
3Department of Medicinal Chemistry, Faculty of Pharmacy, Port Said University
4Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519-Minia, Egypt.
Abstract
Indolin-2-one is a pharmacologically beneficial scaffold with several biological features. The role of oxindole may be recognized to be varied by various chemical groups to provide novel biological activities as a chemical scaffold for creating and developing biologically active drugs. Cancer treatment has advanced significantly in recent years. The oxindole multitarget kinase inhibitor sunitinib, which is taken orally, inhibits specific receptor tyrosine kinases. Sunitinib has shown potential anticancer impact in phase II trials of individuals with diverse cancers, including hepatocellular carcinoma, pancreatic neuroendocrine tumors, and renal cell carcinoma. The most frequent adverse effects of sunitinib, pharmacokinetic/pharmacodynamic studies, drug-drug interactions, and mechanism of action of sunitinib are also discussed. The review focuses on resistance developed in almost all responding patients, a significant cause of therapy failure. More studies are needed to investigate the mechanisms of antiangiogenic agent resistance to discover new analogs capable of circumventing antiangiogenic agent resistance with better therapeutic properties.
Keywords
Sunitinib; Indolin-2-one; Kinase inhibition; Toxicity; Resistance
Statistics
Article View: 181
PDF Download: 107